Predix: Phase 2 study shows PRX-00023 reduces symptoms in generalized anxiety disorder

By Lisa Kerner

Charlotte, N.C., June 13 - Predix Pharmaceuticals said a four-week, open-label phase 2 clinical trial of its lead drug candidate, PRX-00023, showed significantly reduced symptoms and was well-tolerated in the 21 study participants with generalized anxiety disorder (GAD).

Symptom reduction was measured by the Hamilton Anxiety Rating Scale (HAM-A).

Six of the 19 patients (32%) with week 4 evaluations achieved remission criteria based on the HAM-A, while 52% had a 50% or greater reduction in the HAM-A total scale.

"The phase 2 data suggest that PRX-00023 has the potential to meet the significant unmet medical need for a once-daily treatment to relieve anxiety without the troublesome side effects associated with many of the other drugs used to treat this disorder," lead investigator Sanjay J. Mathew said in a company news release.

"A phase 3 clinical trial is ongoing with PRX-00023, and the results from that study will provide further clinical insight into the efficacy and tolerability of this drug candidate in generalized anxiety."

The company presented the results at the 46th Annual New Clinical Drug Evaluation Unit meeting in Boca Raton, Fla.

Predix, based in Lexington, Mass., is a pharmaceutical company focused on the discovery and development of novel small-molecule drugs that target G-Protein Coupled Receptors and ion channels.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.